Your AI-Trained Oncology Knowledge Connection!
Ongoing clinical trials are exploring the cytoreductive properties and immunogenic potential of stereotactic radiation in the treatment of patients with metastatic kidney cancer, according to an expert from the University of Texas Southwestern Medical Center.
Gavin Jones, MD, and colleagues explore the landscape of radiation therapy in diffuse large B-cell lymphoma.
Results from the phase 2 ARC-7 trial found that zimberelimab, etrumadenant, and domvanalimab enhanced efficacy outcomes in patients with advanced non–small cell lung cancer.
The FDA has set the Prescription Drug User Fee Act date for April 21, 2023 for each supplemental biologics license application of enfortumab vedotin-ejfv and pembrolizumab in urothelial carcinoma.
Following the 2022 ASH Annual Meeting and Exposition, Nakhle Saba, MD; Lindsey Roeker, MD; Javier Pinilla, MD, PhD; and Catherine C. Coombs, MD, participated in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics ranged from most exciting data in chronic lymphocytic leukemia and lymphoma, as well as what research needs more follow-up.
Joseph Mikhael, MD, and Hakan Kaya, MD, review key efficacy and safety data for the combination of selinexor, carfilzomib, and dexamethasone in R/R MM and discuss optimal dosing and adverse event management strategies for selinexor.
The FDA has approved the Agilent Resolution ctDx FIRST assay for identifying patients with KRAS G12C–mutated non–small cell lung cancer who may benefit from adagrasib.
An expanded indication for pafolacianine as an imaging agent for patients with lung cancer has been approved by the FDA based on findings from the phase 3 ELUCIDATE trial.
Ravi Vij, MD, MBA, suggested that 4-drug regimens may be a new standard for frontline therapy in newly diagnosed multiple myeloma, as oncologists await trial readouts from ongoing clinical trials.
Ravi Vij, MD, MBA, offered additional information about the use of various regimens aimed to treat patients with high-risk, newly diagnosed multiple myeloma, that were read out at the 2022 ASH Annual Meeting.
Fam-trastuzumab deruxtecan-nxki has been recommended for approval by the European Union’s Committee for Medicinal Products for Human Use in patients with HER2-low advanced breast cancer.
Ravi Vij, MD, MBA, discussed updated analyses of the phase 3 SWOG S0777 trial, supporting the use of bortezomib, lenalidomide, and dexamethasone in untreated patients with multiple myeloma who do not plan on receiving immediate autologous stem cell transplant.
“Much more research” is needed to advance the adjuvant treatment of patients with kidney cancer, according to an expert from the Royal Free London NHS Foundation Trust.
Ken Shain, MD, PhD, pinpoints the critical, lingering gaps in patient access to cellular immunotherapies in multiple myeloma.
Ken Shain, MD, PhD, provides an overview of developments on the horizon in multiple myeloma.
Ken Shain, MD, PhD, spoke about the dramatic impact of novel immunotherapies in the multiple myeloma treatment landscape, as well as other updates from the 2022 ASH Annual Meeting and Exposition.
Ken Shain, MD, PhD, discussed some of the research in multiple myeloma that was featured in a recent FaceOff program, and how these recent advances may change the standard of care.
Referring responders with chemotherapy-sensitive relapsed/refractory diffuse large B-cell lymphoma who achieved a partial response or better to transplantation resulted in an improved overall survival vs those undergoing additional lines of therapy.
The original guidance was published as a draft 2 years ago, detailing the FDA's thoughts on the development of agents for the treatment of acute myeloid leukemia.
The FDA has approved an additional indication for pemetrexed injection plus pembrolizumab and chemotherapy in the treatment of metastatic non–small cell lung cancer without EGFR or ALK tumor aberrations.
In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.
The FDA has now requested that the manufacturer of melphalan flufenamide withdraw the multiple myeloma drug from the United States market months after the drug developer rescinded a letter voluntarily withdrawing the therapeutic.
Patients in China diagnosed with high-risk neuroblastoma can now receive treatment with naxitamab-gqgk, which was recently given the greenlight by the National Medical Products Administration.
177Lu vipivotide tetraxetan becomes first targeted radioligand treatment approved by the European Commission for prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.
Patients with high-risk Bacillus Calmette Guérin–unresponsive non-muscle invasive bladder cancer can now receive treatment with nadofaragene firadenovec-vncg—the first gene therapy—following its approval by the FDA.
Non-Hispanic Black patients appeared to have higher disease-specific mortality rates than patients of other races, with clinicopathologic factors playing the greatest role in the disparity.
Findings from the phase 3 CONTACT-01 trial indicated that cabozantinib and atezolizumab did not reach the primary end point of overall survival in patients with metastatic non–small cell lung cancer.
Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center.
During the 2022 San Antonio Breast Cancer Symposium, Neil M. Iyengar, MD, took over the CancerNetwork® Twitter to review key presentation takeaways.
The FDA’s approval of new indications and dosing regimens of capecitabine across several cancer types, including breast cancer and colon cancer, marks the first drug to receive an update under the agency’s Project Renewal program.
